MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
PHVS Pharvaris
- 19.570
- +0.560+2.95%
Close Dec 20 16:00 ET
- 19.570
- 0.0000.00%
Post 16:00 ET
1.06BMarket Cap-7.26P/E (TTM)
20.480High18.770Low97.07KVolume19.000Open19.010Pre Close1.91MTurnover0.51%Turnover RatioLossP/E (Static)54.23MShares33.00052wk High3.45P/B371.40MFloat Cap15.37052wk Low--Dividend TTM18.98MShs Float42.860Historical High--Div YieldTTM9.00%Amplitude1.770Historical Low19.727Avg Price1Lot Size
About Pharvaris Company
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
Company Profile
SymbolPHVS
Company NamePharvaris
Listing DateFeb 5, 2021
Issue Price20.00
Founded2015
CEOMr. Berndt Modig
MarketNASDAQ
Employees82
Fiscal Year Ends12-31
AddressEmmy Noetherweg 2
CityLeiden
ProvinceZuid-Holland
CountryNetherlands (the)
Zip Code2333 BK
Phone31-71-203-64-10
Websitehttp://www.pharvaris.com
Company Executives
- Name
- Position
- Salary
- Berndt Modig
- Chief Executive Officer and Executive Director
- 935.28K
- Joan Schmidt
- Chief Legal Officer
- --
- Dr. Wim Souverijns, PhD
- Chief Community Engagement and Commercial Officer
- --
- Dr. Morgan Conn, PhD
- Chief Business Officer
- --
- Dr. Anne Lesage, PhD
- Chief Early Development Officer
- --
- Annick Deschoolmeester
- Chief Human Resources Officer
- --
- Dr. Peng Lu, M.D.,PhD
- Chief Medical Officer
- --
- Dr. Stefan Abele, PhD
- Chief Technical Operations Officer
- --
- Anna Nijdam, M.Sc.
- Head of Strategic Finance and Principal Accounting Officer
- --
- Viviane Monges
- Independent Director
- 62.50K
- Hans Schikan, Pharm.D.
- Independent Director
- 61.00K
- Dr. David P. Meeker,M.D.
- Independent Director
- 94.00K
- Dr. Robert Glassman, M.D.
- Independent Director
- 50.50K
- Dr. Elisabeth Bjork, M.D.,PhD
- Independent Director
- 45.00K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.